Akèy › Kansè fwa (Kasinòm epatoselilè) › Washington › Seattle
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Seattle, WA
10 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Ap rekriteFaz 1/2
- Research Facility, Seattle
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Ap rekriteFaz 1/2
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center- Montlake, Seattle
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Ap rekriteFaz 1/2
- Local Institution - 0083, Seattle
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Ap rekriteFaz 1/2
- Fred Hutchinson Cancer Center, University of Washington, Seattle
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Ap rekriteFaz 3
- Research Site, Seattle
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- University of Washington School of Medicine, Seattle
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Ap rekrite
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Ap rekriteFaz 1/2
- Virginia Mason Medical Center, Seattle
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Ap rekriteFaz 1
- Seattle Children's Hospital, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Seattle
Etid Kansè fwa (Kasinòm epatoselilè) nan lòt vil
- Houston, TX31 etid
- New York City, NY24 etid
- Dallas, TX19 etid
- Los Angeles, CA19 etid
- Boston, MA18 etid
- Cleveland, OH18 etid
- Philadelphia, PA16 etid
- Chicago, IL16 etid
- Pittsburgh, PA15 etid
- San Francisco, CA14 etid
- Orange, CA14 etid
- Jacksonville, FL14 etid
Lòt etid nan Seattle
- Kansè Poumon ki pa ti selil53 etid
- Kansè (tout kalite)49 etid
- Kansè pwostat42 etid
- Leksemi mieloïd egi41 etid
- Kansè nan tete39 etid
- Kansè Metastatik39 etid
- Kansè kolorektal34 etid
- Kansè poumon33 etid
- Kansè ovè30 etid
- Myelom Miltip22 etid
- Kansè vejik21 etid
- Sendwòm myelodisplastik21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.